ClinicalTrials.gg
Not yet recruitingNCT07937332OXFORDUpdated Nov 16, 2026

OXytocin For Opioid Respiratory Depression

A Phase 2 interventional study of Intranasal Oxytocin 40 i.u. and Intranasal Placebo Spray in Chronic Pain, Intranasal Drug Administration and Oxytocin, sponsored by George Washington University. Not yet recruiting. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-16.

Sponsored by George Washington University · Phase 2, Interventional, and Prevention

Updated Nov 16, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
100
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

Opioid medications are a significant component of the management of chronic pain. Chronic use of opioids disrupts sleep architecture and cause respiratory depression, which is particularly prevalent during sleep. Chronic opioids induce sleep disordered breathing (SDB) including sleep hypoventilation, central sleep apnea and obstructive sleep apnea (OSA). It was previously shown that oxytocin can treat SDB. There is emerging evidence that oxytocin can treat substance use disorder and has analgesic properties. Oxytocin efficacy of prevention of respiratory depression after acute opioid use will be examined as well as oxytocin efficacy in chronic opioid use.

Read the detailed description

Intranasal oxytocin to prevent opioid-induced respiratory depression, reduce pain and the opioid dose in patients on chronic opioids (OXytocin For Opioid Respiratory Depression). OXFORD will test in a double blinded, placebo-controlled phase 2 clinical trial, the therapeutic efficacy of OXYTOCIN in decreasing A) the severity of sleep disordered breathing (SDB); B) pain perception, C) the opioid dose and D) drug liking in patients on chronic opioid therapy for chronic pain. Opioid medications are a significant component of the management of chronic pain. Chronic use of opioids disrupts sleep architecture and cause respiratory depression, which is particularly prevalent during sleep. Chronic opioids induce SDB including sleep hypoventilation, central sleep apnea and OSA. It was previously shown that OXYTOCIN can treat Sleep Disordered Breathing (SDB). There is emerging evidence that OXYTOCIN can treat substance use disorder and has analgesic properties. OXFORD will examine OXYTOCIN efficacy for prevention of respiratory depression after acute opioid use.

02

Conditions studied

  • Chronic Pain
  • Intranasal Drug Administration
  • Oxytocin
  • Chronic Pain (Back / Neck)

Browse trials for

Keywords

  • OXFORD
  • intranasal oxytocin
  • opioid induced respiratory depression
  • OIRD
03

In context

Chronic Pain

3,228 studies on the registry are indexed under Chronic Pain; 728 are open to participants now.

This study's planned enrollment of 100 is above the median of 60 across 2,387 interventional studies indexed under Chronic Pain.

Browse Chronic Pain studies →

Lead sponsor

George Washington University is the lead sponsor of 193 studies on the registry; 35 are open to participants now.

Of its 13 completed or terminated interventional studies of FDA-regulated products, 11 (85%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. ≥ 18 years of age
  2. Treated for chronic pain with ≥ 30 milligram morphine equivalent (MME)
  3. Able and willing to provide
  4. Women of will be required to use a highly effective form of in order to be included in the study

Exclusion criteria

Exclusion Criteria:

  1. OSA patients on CPAP therapy
  2. Baseline home sleep testing with > than 10 minutes with a baseline oxygen saturation \<=85%
  3. Unstable cardiovascular disease (decompensated CHF, myocardial infarction or revascularization procedures, and unstable arrhythmias)
  4. Uncontrolled hypertension (BP > 190/110)
  5. or another intrinsic lung disease
  6. Chronic sinusitis requiring surgical treatment (except septal deviation)
  7. Chronic muscle weakness
  8. Chronic daytime hypoxemia (PaO2 \< 70) or hypercapnia (PaCO2 ≥ 45 mmHg)
  9. Chronic supplemental oxygen use
  10. Renal failure on dialysis
  11. Diabetes mellitus requiring insulin
  12. Diabetic neuropathy
  13. Previous surgery for OSA (laser-assisted uvulopalatoplasty, LAUP or uvulopalatopharyngoplasty)
  14. Hypoglossal nerve stimulator
  15. Allergy to oxytocin
  16. Pregnancy
  17. Premenopausal women, who are not on
  18. Any change in non-opioid medications and non-pharmacological interventions during the OXYTOCIN trial
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

05

Study design

Phase
Phase 2
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
100 participants (estimated)

Study arms

  • Active comparator
    Intranasal Oxytocin

    Intranasal oxytocin

    Drug: Intranasal Oxytocin 40 i.u.

  • Placebo comparator
    Intranasal Placebo

    Intranasal placebo

    Drug: Intranasal Placebo Spray

Interventions

  • DrugIntranasal Oxytocin 40 i.u.

    Intranasal oxytocin dose of 40 international units

  • DrugIntranasal Placebo Spray

    This is a placebo comparator intranasal spray

06

What researchers measure

Primary outcomes

  1. Hypopnea on home sleep testing

    Number of hypopnea events on home sleep testing

    Time frame: Beginning of study (Day 1, baseline) and the night before day 28 visit

  2. Oxytocin Level

    Urinary level of oxytocin

    Time frame: During day 28 visit

  3. Respiratory Rate

    Duration of significant increases in respiratory rate

    Time frame: Baseline (Day 1) and second sleep apnea testing (the night before day 28 visit)

  4. Short form McGill Questionnaire

    0-45, higher is more pain

    Time frame: Day 1 and Day 30 of study

  5. Visual Analogue Pain Scale

    0-10, higher is more pain

    Time frame: Day 1 and Day 30 of study

  6. Drug liking and high questionnaire

    0-16, higher is more drug effect from pain medications

    Time frame: Day 1 and Day 30 of study

  7. Short form brief pain inventory

    0-120, higher is more pain

    Time frame: Day 1 and Day 30 of study

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for May 2027; primary completion for Jul 2029, 25 months later.

Of 47 non-industry phase 2 interventional studies under Chronic Pain, half reached primary completion within 42 months of starting (the median), counting those still running; a quarter within 25 and three quarters within 52. This study's planned 25 months is below that.

Counting every sponsor, half of 60 studies reached it within 37 months; a quarter within 21 and three quarters within 52.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 22, 2026
First posted
Nov 16, 2026
StartEst.
May 15, 2027
Primary completionEst.
Jul 14, 2029
CompletionEst.
Jul 14, 2030
Last update
Nov 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 16, 2026
Show all 1 update
  1. Nov 16, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07937332
Responsible party
Vsevolod Polotsky (Vice Chair for Research, George Washington University) — Principal investigator
First posted
Nov 16, 2026
Start date
May 15, 2027 (estimated)
Primary completion
Jul 14, 2029 (estimated)
Completion
Jul 14, 2030 (estimated)
Last update
Nov 16, 2026

Study contacts

Eduard R Research Manager
Contact
eshaykhinurov@mfa.gwu.edu
2022038960

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion